Target
FMS-like tyrosine kinase 3 (FLT3)
2 abstracts
Abstract
A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).Org: MD Anderson Cancer Center Madrid, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS, Universitätsklinikum Jena, Technische Universität Dresden, Curis Inc,